Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors

Journal of Virology

Volumn 88, Issue 17, 2014, Pages 9683-9692

  Hassounah, Said A ^a,b   Mesplède, Thibault ^a   Quashie, Peter K ^a,b   Oliveira, Maureen ^a   Sandstrom, Paul A ^c   Wainberg, Mark A ^a,b,d  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRROLIDONE DERIVATIVE; ANTIVIRUS AGENT; DOLUTEGRAVIR; ELVITEGRAVIR; FUSED HETEROCYCLIC RINGS; INTEGRASE; MUTANT PROTEIN; P31 INTEGRASE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; QUINOLONE DERIVATIVE; RALTEGRAVIR;

AMINO ACID SUBSTITUTION; ANIMAL; ANTIVIRAL RESISTANCE; CELL CULTURE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MICROBIAL SENSITIVITY TEST; PHYSIOLOGY; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; DRUG RESISTANCE, VIRAL; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INTEGRASE; HIV-1; HUMANS; MACACA MULATTA; MICROBIAL SENSITIVITY TESTS; MUTANT PROTEINS; PYRROLIDINONES; QUINOLONES; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 84921962113     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00947-14     Document Type: Article

References (72)

1. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Gunthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA. 2012. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-U.S.A. panel. JAMA 308:387-402. http://dx.doi.org/10.1001/jama.2012.7961.
2. Evans DT, Silvestri G. 2013. Nonhuman primate models in AIDS research. Curr. Opin. HIV AIDS 8:255-261. http://dx.doi.org/10.1097/COH.0b013e328361cee8.
3. Hatziioannou T, Evans DT. 2012. Animal models for HIV/AIDS research. Nat. Rev. Microbiol. 10:852-867. http://dx.doi.org/10.1038/nrmicro2911.
4. Schmitz JE, Korioth-Schmitz B. 2013. Immunopathogenesis of simian immunodeficiency virus infection in nonhuman primates. Curr. Opin. HIV AIDS 8:273-279. http://dx.doi.org/10.1097/COH.0b013e328361cf5b.
5. Hazuda DJ, Young SD, Guare JP, Anthony NJ, Gomez RP, Wai JS, Vacca JP, Handt L, Motzel SL, Klein HJ, Dornadula G, Danovich RM, Witmer MV, Wilson KA, Tussey L, Schleif WA, Gabryelski LS, Jin L, Miller MD, Casimiro DR, Emini EA, Shiver JW. 2004. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 305:528-532. http://dx.doi.org/10.1126/science.1098632.
6. Chirch LM, Morrison S, Steigbigel RT. 2009. Treatment of HIV infection with raltegravir. Expert Opin. Pharmacother. 10:1203-1211. http://dx.doi.org/10.1517/14656560902911488.
7. Lewis MG, Norelli S, Collins M, Barreca ML, Iraci N, Chirullo B, Yalley-Ogunro J, Greenhouse J, Titti F, Garaci E, Savarino A. 2010. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology 7:21. http://dx.doi.org/10.1186/1742-4690-7-21.
8. Anonymous. 2007. FDA approves raltegravir tablets. AIDS Patient Care STDS 21:889. http://dx.doi.org/10.1089/apc.2007.9967.
9. Temesgen Z. 2012. Cobicistat-boosted elvitegravir-based fixed-dose combination antiretroviral therapy for HIV infection. Drugs Today (Barc.) 48:765-771.
10. Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, Piscitelli SC. 2010. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob. Agents Chemother. 54:254-258. http://dx.doi.org/10.1128/AAC.00842-09.
11. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Gilde LR, Wan H, Miller MD, Wenning LA, Teppler H. 2007. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr. 46:125-133. http://dx.doi.org/10.1097/QAI.0b013e318157131c.
12. Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu YP, Zhong L, Margot N, Cheng AK, Chuck SL. 2012. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect. Dis. 12: 27-35. http://dx.doi.org/10.1016/S1473-3099(11)70249-3.
13. Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S. 2013. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 381: 735-743. http://dx.doi.org/10.1016/S0140-6736(12)61853-4.
14. LaFemina RL, Schneider CL, Robbins HL, Callahan PL, LeGrow K, Roth E, Schleif WA, Emini EA. 1992. Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J. Virol. 66:7414-7419.
15. Mesplede T, Quashie PK, Wainberg MA. 2012. Resistance to HIV integrase inhibitors. Curr. Opin. HIV AIDS 7:401-408. http://dx.doi.org/10.1097/COH.0b013e328356db89.
16. Quashie PK, Sloan RD, Wainberg MA. 2012. Novel therapeutic strategies targeting HIV integrase. BMC Med. 10:34. http://dx.doi.org/10.1186/1741-7015-10-34.
17. Hazuda DJ. 2010. Resistance to inhibitors of the human immunodeficiency virus type 1 integration. Braz. J. Infect. Dis. 14:513-518. http://dx.doi.org/10.1590/S1413-86702010000500016.
18. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 359:355-365. http://dx.doi.org/10.1056/NEJMoa0708978.
19. Marinello J, Marchand C, Mott BT, Bain A, Thomas CJ, Pommier Y. 2008. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 47:9345-9354. http://dx.doi.org/10.1021/bi800791q.
20. McColl DJ, Chen X. 2010. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antivir. Res. 85:101-118. http://dx.doi.org/10.1016/j.antiviral.2009.11.004.
21. Quashie PK, Mesplede T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, Underwood MR, Wainberg MA. 2012. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J. Virol. 86:2696-2705. http://dx.doi.org/10.1128/JVI.06591-11.
22. Bar-Magen T, Sloan RD, Donahue DA, Kuhl BD, Zabeida A, Xu H, Oliveira M, Hazuda DJ, Wainberg MA. 2010. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J. Virol. 84:9210-9216. http://dx.doi.org/10.1128/JVI.01164-10.
23. Charpentier C, Roquebert B, Delelis O, Larrouy L, Matheron S, Tubiana R, Karmochkine M, Duval X, Chene G, Storto A, Collin G, Benard A, Damond F, Mouscadet JF, Brun-Vezinet F, Descamps D. 2011. Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir. Antimicrob. Agents Chemother. 55:1293-1295. http://dx.doi.org/10.1128/AAC.00942-10.
24. Underwood MR, Johns BA, Sato A, Martin JN, Deeks SG, Fujiwara T. 2012. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J. Acquir. Immune Defic. Syndr. 61:297-301. http://dx.doi.org/10.1097/QAI.0b013e31826bfd02.
25. Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, Foster SA, Hazen RJ, Miki S, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T, Kawasuji T, Johns BA, Underwood MR, Garvey EP, Sato A, Fujiwara T. 2011. In Vitro antiretroviral properties of S/GSK1349572, a nextgeneration HIV integrase inhibitor. Antimicrob. Agents Chemother. 55:813-821. http://dx.doi.org/10.1128/AAC.01209-10.
26. Hightower KE, Wang R, Deanda F, Johns BA, Weaver K, Shen Y, Tomberlin GH, Carter HL, III, Broderick T, Sigethy S, Seki T, Kobayashi M, Underwood MR. 2011. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob. Agents Chemother. 55:4552-4559. http://dx.doi.org/10.1128/AAC.00157-11.
27. Wares M, Mesplede T, Quashie PK, Osman N, Han Y, Wainberg MA. 2014. The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology 11:7. http://dx.doi.org/10.1186/1742-4690-11-7.
28. Mesplede T, Quashie PK, Osman N, Han Y, Singhroy DN, Lie Y, Petropoulos CJ, Huang W, Wainberg MA. 2013. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 10: 22. http://dx.doi.org/10.1186/1742-4690-10-22.
29. Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P. 2010. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464:232-236. http://dx.doi.org/10.1038/nature08784.
30. Xu HT, Asahchop EL, Oliveira M, Quashie PK, Quan Y, Brenner BG, Wainberg MA. 2011. Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J. Virol. 85:11300-11308. http://dx.doi.org/10.1128/JVI.05584-11.
31. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, Mc-William H, Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG. 2007. CLUSTAL W and CLUSTAL X version 2.0. Bioinformatics23:2947-2948.http://dx.doi.org/10.1093/bioinformatics/btm404.
32. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Soding J, Thompson JD, Higgins DG. 2011. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 7:539. http://dx.doi.org/10.1038/msb.2011.75.
33. Maertens GN, Hare S, Cherepanov P. 2010. The mechanism of retroviral integration from X-ray structures of its key intermediates. Nature 468: 326-329. http://dx.doi.org/10.1038/nature09517.
34. Zhang Y. 2009. I-TASSER: fully automated protein structure prediction in CASP8. Proteins 77(Suppl 9):S100-S113. http://dx.doi.org/10.1002/prot.22588.
35. Bhuyan MS, Gao X. 2011. A protein-dependent side chain rotamer library. BMC Bioinformatics 12(Suppl 14):S10. http://dx.doi.org/10.1186/1471-2105-12-S14-S10.
36. Bower MJ, Cohen FE, Dunbrack RL, Jr. 1997. Prediction of protein side chain rotamers from a backbone-dependent rotamer library: a new homology modeling tool. J. Mol. Biol. 267:1268-1282. http://dx.doi.org/10.1006/jmbi.1997.0926.
37. Krieger E, Joo K, Lee J, Lee J, Raman S, Thompson J, Tyka M, Baker D, Karplus K. 2009. Improving physical realism, stereochemistry, and side chain accuracy in homology modeling: four approaches that performed well in CASP8. Proteins 77(Suppl 9):S114-S122.
38. Menendez-Arias L. 2013. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antivir. Res. 98:93-120. http://dx.doi.org/10.1016/j.antiviral.2013.01.007.
39. Chen Z, Yan Y, Munshi S, Li Y, Zugay-Murphy J, Xu B, Witmer M, Felock P, Wolfe A, Sardana V, Emini EA, Hazuda D, Kuo LC. 2000. X-ray structure of simian immunodeficiency virus integrase containing the core and C-terminal domain (residues 50-293): an initial glance of the viral DNA binding platform. J. Mol. Biol. 296:521-533. http://dx.doi.org/10.1006/jmbi.1999.3451.
40. Snásel J, Krejcik Z, Jencova V, Rosenberg I, Ruml T, Alexandratos J, Gustchina A, Pichova I. 2005. Integrase of Mason-Pfizer monkey virus. FEBS J. 272:203-216.
41. Cherepanov P, Maertens GN, Hare S. 2011. Structural insights into the retroviral DNA integration apparatus. Curr. Opin. Struct. Biol. 21:249-256. http://dx.doi.org/10.1016/j.sbi.2010.12.005.
42. Hare S, Smith SJ, Metifiot M, Jaxa-Chamiec A, Pommier Y, Hughes SH, Cherepanov P. 2011. Structural and functional analyses of the secondgeneration integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol. Pharmacol. 80:565-572. http://dx.doi.org/10.1124/mol.111.073189.
43. Krishnan L, Li X, Naraharisetty HL, Hare S, Cherepanov P, Engelman A. 2010. Structure-based modeling of the functional HIV-1 intasome and its inhibition. Proc. Natl. Acad. Sci. U. S. A. 107:15910-15915. http://dx.doi.org/10.1073/pnas.1002346107.
44. Dobard C, Sharma S, Parikh UM, West R, Taylor A, Martin A, Pau CP, Hanson DL, Lipscomb J, Smith J, Novembre F, Hazuda D, Garcia-Lerma JG, Heneine W. 2014. Postexposure protection of macaques from vaginal SHIV infection by topical integrase inhibitors. Sci. Transl. Med. 6:227ra235. http://dx.doi.org/10.1126/scitranslmed.3007701.
45. Goethals O, Clayton R, Van Ginderen M, Vereycken I, Wagemans E, Geluykens P, Dockx K, Strijbos R, Smits V, Vos A, Meersseman G, Jochmans D, Vermeire K, Schols D, Hallenberger S, Hertogs K. 2008. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J. Virol. 82:10366-10374. http://dx.doi.org/10.1128/JVI.00470-08.
46. Mouscadet JF, Delelis O, Marcelin AG, Tchertanov L. 2010. Resistance to HIV-1 integrase inhibitors: a structural perspective. Drug Resist. Update 13:139-150. http://dx.doi.org/10.1016/j.drup.2010.05.001.
47. Van Wesenbeeck L, Rondelez E, Feyaerts M, Verheyen A, Van der Borght K, Smits V, Cleybergh C, De Wolf H, Van Baelen K, Stuyver LJ. 2011. Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates. Antimicrob. Agents Chemother. 55:321-325. http://dx.doi.org/10.1128/AAC.01733-09.
48. Metifiot M, Vandegraaff N, Maddali K, Naumova A, Zhang X, Rhodes D, Marchand C, Pommier Y. 2011. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS 25:1175-1178. http://dx.doi.org/10.1097/QAD.0b013e3283473599.
49. Quashie PK, Mesplede T, Han YS, Veres T, Osman N, Hassounah S, Sloan RD, Xu HT, Wainberg MA. 2013. Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase. Antimicrob. Agents Chemother. 57:6223-6235. http://dx.doi.org/10.1128/AAC.01835-13.
50. Delelis O, Thierry S, Subra F, Simon F, Malet I, Alloui C, Sayon S, Calvez V, Deprez E, Marcelin AG, Tchertanov L, Mouscadet JF. 2010. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob. Agents Chemother. 54:491-501. http://dx.doi.org/10.1128/AAC.01075-09.
51. Nakahara K, Wakasa-Morimoto C, Kobayashi M, Miki S, Noshi T, Seki T, Kanamori-Koyama M, Kawauchi S, Suyama A, Fujishita T, Yoshinaga T, Garvey EP, Johns BA, Foster SA, Underwood MR, Sato A, Fujiwara T. 2009. Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics. Antivir. Res. 81:141-146. http://dx.doi.org/10.1016/j.antiviral.2008.10.007.
52. Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, Ye L, Niedziela-Majka A, Barnes TL, Novikov N, Chen X, Svarovskaia ES, McColl DJ, White KL, Miller MD. 2013. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob. Agents Chemother. 57: 2654-2663. http://dx.doi.org/10.1128/AAC.02568-12.
53. Delelis O, Malet I, Na L, Tchertanov L, Calvez V, Marcelin AG, Subra F, Deprez E, Mouscadet JF. 2009. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res. 37:1193-1201. http://dx.doi.org/10.1093/nar/gkn1050.
54. Fransen S, Gupta S, Danovich R, Hazuda D, Miller M, Witmer M, Petropoulos CJ, Huang W. 2009. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J. Virol. 83:11440-11446. http://dx.doi.org/10.1128/JVI.01168-09.
55. Mbisa JL, Martin SA, Cane PA. 2011. Patterns of resistance development with integrase inhibitors in HIV. Infect. Drug Resist. 4:65-76. http://dx.doi.org/10.2147/IDR.S7775.
56. Naidu YM, Kestler HW, III, Li Y, Butler CV, Silva DP, Schmidt DK, Troup CD, Sehgal PK, Sonigo P, Daniel MD, et al. 1988. Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: persistent infection of rhesus monkeys with molecularly cloned SIVmac. J. Virol. 62:4691-4696.
57. Savarino A, Pistello M, D'Ostilio D, Zabogli E, Taglia F, Mancini F, Ferro S, Matteucci D, De Luca L, Barreca ML, Ciervo A, Chimirri A, Ciccozzi M, Bendinelli M. 2007. Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitro and provide a rationale to redesign antiretroviral treatment for feline AIDS. Retrovirology 4:79. http://dx.doi.org/10.1186/1742-4690-4-79.
58. Valkov E, Gupta SS, Hare S, Helander A, Roversi P, McClure M, Cherepanov P. 2009. Functional and structural characterization of the integrase from the prototype foamy virus. Nucleic Acids Res. 37:243-255. http://dx.doi.org/10.1093/nar/gkn938.
59. Chen Z, Luckay A, Sodora DL, Telfer P, Reed P, Gettie A, Kanu JM, Sadek RF, Yee J, Ho DD, Zhang L, Marx PA. 1997. Human immunodeficiency virus type 2 (HIV-2) seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian immunodeficiency virus-infected sooty mangabeys. J. Virol. 71:3953-3960.
60. Courgnaud V, Pourrut X, Bibollet-Ruche F, Mpoudi-Ngole E, Bourgeois A, Delaporte E, Peeters M. 2001. Characterization of a novel simian immunodeficiency virus from guereza colobus monkeys (Colobus guereza) in Cameroon: a new lineage in the nonhuman primate lentivirus family. J. Virol. 75:857-866. http://dx.doi.org/10.1128/JVI.75.2.857-866.2001.
61. Hahn BH, Shaw GM, De Cock KM, Sharp PM. 2000. AIDS as a zoonosis: scientific and public health implications. Science 287:607-614. http://dx.doi.org/10.1126/science.287.5453.607.
62. Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, Cummins LB, Arthur LO, Peeters M, Shaw GM, Sharp PM, Hahn BH. 1999. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397:436-441. http://dx.doi.org/10.1038/17130.
63. Hirsch VM, Campbell BJ, Bailes E, Goeken R, Brown C, Elkins WR, Axthelm M, Murphey-Corb M, Sharp PM. 1999. Characterization of a novel simian immunodeficiency virus (SIV) from L'Hoest monkeys (Cercopithecus l'hoesti): implications for the origins of SIVmnd and other primate lentiviruses. J. Virol. 73:1036-1045.
64. Simon F, Mauclere P, Roques P, Loussert-Ajaka I, Muller-Trutwin MC, Saragosti S, Georges-Courbot MC, Barre-Sinoussi F, Brun-Vezinet F. 1998. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat. Med. 4:1032-1037. http://dx.doi.org/10.1038/2017.
65. Wain-Hobson S. 1998. More ado about HIV's origins. Nat. Med. 4:1001-1002. http://dx.doi.org/10.1038/1986.
66. Weiss RA, Wrangham RW. 1999. From Pan to pandemic. Nature 397: 385-386. http://dx.doi.org/10.1038/17008.
67. Ni XJ, Delelis O, Charpentier C, Storto A, Collin G, Damond F, Descamps D, Mouscadet JF. 2011. G140S/Q148R and N155H mutations render HIV-2 integrase resistant to raltegravir, whereas Y143C does not. Retrovirology 8:68. http://dx.doi.org/10.1186/1742-4690-8-68.
68. Smith RA, Raugi DN, Kiviat NB, Hawes SE, Mullins JI, Sow PS, Gottlieb GS. 2011. Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance. AIDS 25:2235-2241. http://dx.doi.org/10.1097/QAD.0b013e32834d8e52.
69. Smith RA, Raugi DN, Pan C, Coyne M, Hernandez A, Church B, Parker K, Mullins JI, Sow PS, Gottlieb GS. 2012. Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. PLoS One 7:e45372. http://dx.doi.org/10.1371/journal.pone.0045372.
70. Hare S, Vos AM, Clayton RF, Thuring JW, Cummings MD, Cherepanov P. 2010. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc. Natl. Acad. Sci. U. S. A. 107: 20057-20062. http://dx.doi.org/10.1073/pnas.1010246107.
71. Radzio J, Yueh YL, Mitchell J, Jenkins L, Garcia-Lerma JG, Heneine W. 2014. Monthly GSK744 long-acting injections protect macaques against repeated vaginal SHIV exposures, abstr 40LB. Abstr 21st Conf. Retrovir. Opportunistic Infect., Boston, MA.
72. Andrews CD, Spreen WR, Yueh YL, Gettie A, Russell-Lodrigue K, Mohri H, Cheng-Mayer C, Hong Z, Markowitz M, Ho D. 2014. Correlating GSK1265744 plasma levels to prevention of rectal SHIV transmission in macaques, abstr 39. Abstr 21st Conf. Retrovir. Opportunistic Infect., Boston, MA.